|
⚲
|
| Keyboard |
| Sessa Capital IM LP
✚
|
|
|---|---|
| CRD # | 166403 |
| SEC # | 801-79501 |
| CIK # | 0001595849 |
| AUM | 7,524.2 M (2026-03-31) |
| Employees | 13 (54% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-257-4410 |
| Address | 888 Seventh Avenue, 30th Floor New York, NY 10019 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation 5.A. Adviser Compensation Detailed descriptions of fees charged to Investors in the Funds are included in each Fund’s offering documents. In addition, Sessa Capital and the Funds’ general partner have authority to waive or reduce fees charged to certain Investors. Asset-Based Compensation Sessa Capital is paid a management fee, payable quarterly in advance, of no more than 1.5% per year of the value of each Investor’s interest in the Funds, calculated as of the first day of the calendar quarter. Performance-Based Compensation The Funds’ general partner, Sessa Capital GP, LLC is entitled to receive an annual performance- based allocation equal to no more than 20% of the net capital appreciation credited to each Investor in the Funds, subject to a high-water mark. The performance allocation, if any, is generally calculated and determined as of December 31st of each year, but may be calculated on other dates, such as upon the termination of the Fund and the final liquidation of its assets. If an Investor withdraws on a date other than December 31st, the performance allocation will be calculated through the date of withdrawal with respect to such Investor. Any performance-based compensation complies with Rule 205-3 under the Investment Advisers Act of 1940, as amended (the “Advisers Act”). 5.B. Direct Billing of Advisory Fees Management fees and performance allocations are deducted directly from each Fund’s account with its custodian, in accordance with invoices and instructions prepared by Sessa Capital and each Fund’s offering documents. 5.C. Other Non-Advisory Fees The management fee and the performance allocation are exclusive of brokerage commissions, transaction fees, and other related costs and expenses that are incurred by the Funds and indirectly borne by Investors. The Funds incur certain charges for services by custodians, brokers, administrators, lawyers, auditors and other third parties such as custodial fees, wire transfer and electronic fund fees, audit and legal fees, and other fees and taxes on brokerage accounts and securities transactions. The Funds’ portfolios may include positions in mutual funds or exchange traded funds that also charge management fees. Such charges, fees, and commissions are exclusive of, and in addition to, Sessa Capital’s fees. Sessa Capital does not receive any portion of these commissions, fees, and costs. Sessa Capital may identify an investment opportunity or opportunities that have capacity greater than what Sessa Capital can invest on its own. At times, Sessa Capital may, but is not obligated to, offer certain Investors and others the opportunity to participate in the investment opportunity through a managed account, special purpose vehicle or other advisory basis where Sessa Capital may receive compensation or other consideration from the Investors and others who participate in the opportunity. The investments made by the Funds may include “new issue” securities. If a Fund invests in “new issue” securities, the interests of the Investors may be divided into classes, one of which includes those Investors that are eligible to participate in new issue investments, and the other of which includes those Investors that are ineligible. Net profits and net losses on new issues will be allocated to the class of eligible Investors. As a matter of fairness to the Investors who do not participate in gains or losses from new issue securities purchased by a Fund, an appropriate use- of-funds charge, to be determined by the Fund’s general partner in its sole discretion, may be charged to the assets attributable to the capital accounts of those eligible Investors and credited to all capital accounts pro rata in accordance with their respective balances for the applicable fiscal period. Item 12 below describes the factors that Sessa Capital considers in selecting broker-dealers for Fund transactions and determining the reasonableness of their compensation (e.g., commissions). 5.D. Advance Payment of Fees Fees include a management fee, which is generally payable quarterly as of the first day of the quarter. Management fees are charged on a prorated basis with respect to capital contributions accepted on days other than the first business day of a calendar quarter. If any Investor withdraws all or a portion of its capital account from a Fund on any day other than the last day of a calendar quarter, such Investor’s capital account will be credited, on the withdrawal date, with the unearned portion of the management fee attributable to the percentage withdrawn as of such date. 5.E. Compensation for Sale of Securities or Other Investment Products Neither Sessa Capital nor its supervised persons accept compensation for the sale of securities or other investment products, including asset-based sales charges or service fees from the sale of mutual funds. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients Sessa Capital’s clients are Sessa Capital (Master), L.P., Sessa Capital Special Opportunity Fund II, L.P., and Sessa Capital Special Opportunity Fund III, L.P. Sessa Capital, L.P., a Delaware limited partnership and Sessa Capital (International), Ltd., a Cayman Islands exempted company are the feeder entities in a “master-feeder” structure and invest substantially all of their investable assets in Sessa Capital (Master), LP. The minimum initial investment in Sessa Capital (Master), L.P. is $1,000,000 and each additional capital contribution must be in the amount of at least $250,000. The minimum initial investment in Sessa Capital Special Opportunity Fund II, L.P. is $1,000,000 and additional capital contributions may be accepted. The minimum initial investment in Sessa Capital Special Opportunity Fund III, L.P. is $5,000,000 and additional capital contributions may be accepted. The general partner, in its sole discretion, may admit new Investors at any time, may refuse any new investments and may accept initial and additional investments which are lower than the stated minimum. Minimum withdrawal amounts and minimum capital account size may apply in the event of a partial withdrawal. An Investor also may be required to withdraw all or part of its interest in a Fund upon provision of reasonable notice. All Investors must be qualified purchasers and qualified clients. |
| CIK | Period |
|---|---|
| 0001595849 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Discovery Communications Inc | 0.9 | ||
| Humana Inc | 0.6 | ||
| PG&E Corp | 0.4 | ||
| Kimberly Clark Corp | 0.4 | ||
| Illumina Inc | 0.4 | ||
| Air Products & Chemicals Inc /DE/ | 0.3 | ||
| Ally Financial Inc | 0.3 | ||
| Sotera Health Co | 0.3 | ||
| Capital One Financial Corp | 0.3 | ||
| Solstice Advanced Materials Inc | 0.2 | ||
| Teleflex Inc | 0.2 | ||
| Fortress Transportation & Infrastructure Investors LLC | 0.1 | ||
| Coupang Inc | 0.1 | ||
| Tandem Diabetes Care Inc | 0.1 | ||
| Grail Inc | 0.1 | ||
| Coinbase Global Inc | 0.1 | ||
| Robinhood Markets Inc | 0.1 | ||
| Tesla Motors Inc | 0.1 | ||
| Magnum ICE Cream Co NV | 0.1 | ||
| ASA Gold & Precious Metals Ltd | 0.1 | ||
| Axalta Coating Systems Ltd | 0.1 | ||
| Fortrea Holdings Inc | 0.0 | ||
| ROKU Inc | 0.0 | ||
| Lexicon Pharmaceuticals Inc/DE | 0.0 | ||
| Performance Food Group Co | 0.0 | ||
| ASN Technologies Inc | 0.0 | ||
| US Foods Holding Corp | 0.0 | ||
| Duolingo Inc | 0.0 | ||
| Big Cypress Acquisition Corp | 0.0 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Sessa Capital Special Opportunity Fund III LP | [2022-08-29] | 97.4 M | 1.8 M |
| Filed 2023-06-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Special Opportunity Fund II LP | [2019-03-28] | 867.3 M | 1,907.2 M |
| Filed 2026-01-13 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Special Opportunity Fund I LP | [2016-03-30] | 5.7 M | |
| Filed 2016-02-11 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sessa Capital Master LP | [2013-01-02] | 554.2 M | 5,615.2 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 7.5 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 7.5 |
| By Discretionary | ||
| Discretionary | 5 | 7.5 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 7.5 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 1.9 | |
| Total | 5 | 7.5 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Petry | Executive Officer | 6 | 2 | |
| Sessa Capital GP LLC | Director | 4 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001595849] | |
| 3 | [0001595849] | |
| 4 | [0001595849] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300N2WPE2Q4XDV467 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
SAB Biotherapeutics Inc SABS
Common Stock
|
2025-09-29 | Option exercise | 1,740,000 | $1.75 | 3,045,000 |
|
SAB Biotherapeutics Inc SABS
Series B Convertible Preferred Stock · derivative
|
2025-09-29 | Option exercise | 17,400 | ||
|
SAB Biotherapeutics Inc SABS
Series B Convertible Preferred Stock · derivative
|
2025-07-22 | Grant | 228,500 | ||
|
SAB Biotherapeutics Inc SABS
Warrants (right to buy) · derivative
|
2025-07-22 | Grant | 228,500 | ||
|
SAB Biotherapeutics Inc SABS
Warrants (right to buy) · derivative
|
2025-07-22 | Grant | 114,250 | ||
|
Garrett Motion Inc GTX
Common Stock
|
2024-03-06 | Sell | 10,000,000 | $9.00 | 90,000,000 |
|
SAB Biotherapeutics Inc SABS
Series A-2 Convertible Preferred Stock · derivative
|
2023-11-24 | Option exercise | 28,380 | $1,000.00 | 28,380,000 |
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-11-24 | Option exercise | 31,269 | $1,000.00 | 31,269,000 |
|
SAB Biotherapeutics Inc SABS
Common Stock
|
2023-11-24 | Option exercise | 4,584,571 | ||
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-11-13 | Grant | 13,269 | $1,000.00 | 13,269,000 |
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-11-13 | Option exercise | 13,269 | ||
|
SAB Biotherapeutics Inc SABS
Tranche B Warrants · derivative
|
2023-11-10 | Grant | 8,846 | ||
|
SAB Biotherapeutics Inc SABS
Tranche C Warrants · derivative
|
2023-11-10 | Grant | 22,115 | ||
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-11-10 | Grant | 13,269 | ||
|
SAB Biotherapeutics Inc SABS
Series A-1 Convertible Preferred Stock · derivative
|
2023-10-23 | Grant | 16,269 | $1,000.00 | 16,269,000 |
|
SAB Biotherapeutics Inc SABS
Tranche A Warrants · derivative
|
2023-10-23 | Option exercise | 16,269 | ||
|
Garrett Motion Inc GTX
Common Stock
|
2023-06-13 | Option exercise | 1,731,896 | ||
|
Garrett Motion Inc GTX
Series A Preferred Stock · derivative
|
2023-06-06 | Option exercise | 16,592,384 | $0.00 | |
|
Garrett Motion Inc GTX
Common Stock
|
2023-06-06 | Option exercise | 16,592,384 | ||
|
Provention Bio Inc PRVB
Common Stock
|
2023-04-27 | Tender | 15,567,497 | ||
| showing 20 of 30 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Polunin Capital Partners Limited
✚
|
7,959.6 M | |
|
LoanCore Capital Credit Advisor LLC
✚
|
CT | 7,922.4 M |
|
Kensico Capital Management Corp
✚
|
CT | 7,876.6 M |
|
Suvretta Capital Management LLC
✚
|
NY | 7,866.7 M |
|
59 North Capital Management LP
✚
|
TX | 7,503.2 M |
|
Lombard Odier Asset Management USA Corp
✚
|
NY | 7,484.7 M |
|
Morant Wright Management Limited
✚
|
7,430.8 M | |
|
BLS Capital Fondsmaeglerselskab A/S
✚
|
7,218.4 M | |
|
Sachem Head Capital Management LP
✚
|
NY | 7,157.7 M |
|
Daemon Investment and Asset Management LLC
✚
|
FL | 7,098.5 M |